 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 123» |
- | Pifeltro (doravirine) / Merck (MSD), doravirine/islatravir (MK-8591A) / Merck (MSD), islatravir (MK-8591) / Merck (MSD)
Preclinical, Journal: Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro. (Pubmed Central) - May 30, 2025
MuSyC scores showed a negative correlation with doravirine FC values, number of NRTI mutations and presence of M184V/I, but not with islatravir FC values. Doravirine and islatravir may cooperatively inhibit NRTI and NNRTI resistant viruses despite complex mutational profiles, however the accumulation of resistance mutations may reduce the combinatorial activity.
- doravirine/islatravir (MK-8591A) / Merck (MSD)
Switching to Doravirine/Islatravir (100 mg/0.25 mg) once daily maintained viral suppression in the presence of archived M184I/V resistance-associated mutations in proviral DNA () - May 10, 2025 - Abstract #IASHIV2025IAS_HIV_646;
P3
BACKGROUND: In three Phase 3 studies (P051: NCT05631093; P052: NCT05630755; P054: NCT05766501) virologic suppression was maintained in people living with HIV who switched to doravirine/islatravir (DOR/ISL 100 mg/0.25 mg); 2 studies (P051 and P052) were comparative and demonstrated noninferiority to baseline antiretroviral therapy (bART) or bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). Switching to DOR/ISL 100 mg/0.25 mg in Phase 3 clinical studies maintained viral suppression for at least 48 weeks in the presence of preexisting M184I/V in proviral DNA.
- ||| doravirine/islatravir (MK-8591A) / Merck (MSD)
P3 data, Journal, Head-to-Head: Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trial. (Pubmed Central) - Mar 13, 2025
P3
Doravirine/islatravir (100/0.75 mg) once-daily was non-inferior to bictegravir/emtricitabine/tenofovir alafenamide through week 48 for initial HIV-1 treatment. Due to decreases in CD4 and lymphocyte counts, development of this dose of doravirine/islatravir was stopped.
- doravirine/islatravir (MK-8591A) / Merck (MSD)
Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: An Open-Label Phase III Study in Adults With HIV-1 (San Francisco Ballroom B) - Mar 3, 2025 - Abstract #CROI2025CROI_332;
P3
MK-8591A-051 is a phase 3 study evaluating the efficacy and safety of switching from oral ART to DOR/ISL (100/0.25 mg), a once-daily single-tablet regimen...Conclusions Switching to DOR/ISL (100/0.25 mg) maintained viral suppression and was non-inferior to continuing bART at week 48. DOR/ISL was well tolerated with a similar safety profile to bART and did not adversely affect lymphocytes.
- doravirine/islatravir (MK-8591A) / Merck (MSD)
Switch to DOR/ISL (100/0.25 mg) QD From BIC/FTC/TAF: A Blinded Phase III Study in Adults With HIV-1 (San Francisco Ballroom B) - Mar 3, 2025 - Abstract #CROI2025CROI_331;
P3
Conclusions DOR/ISL (100/0.25 mg) maintained viral suppression and was non-inferior to BIC/FTC/TAF at week 48. DOR/ISL was well tolerated with a similar safety profile to BIC/FTC/TAF and did not adversely affect lymphocytes.
- ||||||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Trial completion: Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Na (clinicaltrials.gov) - Feb 24, 2025
P3, N=599, Completed, Sponsor: Merck Sharp & Dohme LLC
DOR/ISL was well tolerated with a similar safety profile to BIC/FTC/TAF and did not adversely affect lymphocytes. Active, not recruiting --> Completed
- || doravirine/islatravir (MK-8591A) / Merck (MSD)
Review, Journal: Doravirine/Islatravir for the treatment of HIV. (Pubmed Central) - Jan 3, 2025
ISL doses as low as 0.25?mg proved non-inferior to current treatments. Therefore, evaluation of the long-term efficacy and safety of DOR/ISL should focus on reduced doses of ISL and minimizing CD4 reduction.
- || doravirine/islatravir (MK-8591A) / Merck (MSD)
New P1 trial, Combination therapy: A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055) (clinicaltrials.gov) - Dec 6, 2024
P1, N=24, Completed, Sponsor: Merck Sharp & Dohme LLC
- ||||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Enrollment closed: DOR/ISL in HIV-1 Antiretroviral Treatment-na (clinicaltrials.gov) - Oct 21, 2024
P3, N=500, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Therefore, evaluation of the long-term efficacy and safety of DOR/ISL should focus on reduced doses of ISL and minimizing CD4 reduction. Recruiting --> Active, not recruiting
- ||||||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Trial completion: Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017) (clinicaltrials.gov) - Sep 27, 2024
P3, N=672, Completed, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Trial completion date: DOR/ISL in HIV-1 Antiretroviral Treatment-na (clinicaltrials.gov) - Sep 20, 2024
P3, N=500, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Active, not recruiting --> Completed Trial completion date: Nov 2026 --> Aug 2029
- doravirine/islatravir (MK-8591A) / Merck (MSD)
The Effect of Pantoprazole on Doravirine/Islatravir Pharmacokinetics (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2820;
- ||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Trial completion date: A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) (clinicaltrials.gov) - Sep 2, 2024
P3, N=650, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Nov 2026 --> Aug 2029 Trial completion date: Jan 2026 --> Sep 2028
- ||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Trial completion date: A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052) (clinicaltrials.gov) - Aug 27, 2024
P3, N=514, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Jan 2026 --> Sep 2028 Trial completion date: Oct 2025 --> Aug 2028
- ||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Trial completion date: A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051) (clinicaltrials.gov) - Aug 22, 2024
P3, N=501, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Oct 2025 --> Aug 2028 Trial completion date: Oct 2025 --> Jul 2028
- | Journal: Challenges for novel antiretroviral development in an era of widespread TLD availability. (Pubmed Central) - Jul 11, 2024
We illustrate when generic TLD will become available worldwide and compare this with trial programmes and approval timelines for two case-study novel ART combinations: islatravir/doravirine and cabotegravir/rilpivirine. We demonstrate that currently these regimens and trial programmes will not meet key benchmarks required to compete with TLD.
- ||| P3 data, Journal, Head-to-Head: Switch to fixed-dose doravirine (100 mg) with islatravir (0 (Pubmed Central) - May 30, 2024
P3
We demonstrate that currently these regimens and trial programmes will not meet key benchmarks required to compete with TLD. Switching to daily doravirine (100 mg) and islatravir (0
- ||| Pifeltro (doravirine) / Merck (MSD), doravirine/islatravir (MK-8591A) / Merck (MSD), islatravir (MK-8591) / Merck (MSD)
P3 data, Journal, Head-to-Head: Switch to fixed-dose doravirine (100 mg) with islatravir (0 (Pubmed Central) - May 30, 2024
P3
Switching to daily doravirine (100 mg) and islatravir (0 Switching to single-tablet doravirine (100 mg) and islatravir (0
- ||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Trial completion date: Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017) (clinicaltrials.gov) - Mar 28, 2024
P3, N=672, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Switching to single-tablet doravirine (100 mg) and islatravir (0 Trial completion date: Mar 2024 --> Nov 2024
- doravirine/islatravir (MK-8591A) / Merck (MSD)
Switching to Doravirine/Islatravir Maintains Viral Suppression Regardless of Archived Mutations (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_1304;
P3
Background: In 2 phase 3 clinical trials, switching to the 2-drug combination doravirine/islatravir (DOR/ISL) 100/0.75mg was non-inferior to continuing the prior antiretroviral (ART) regimen. Switching to DOR/ISL 100/0.75mg maintains viral suppression for up to 96 weeks regardless of archived M184I/V or NNRTI RAMs in proviral DNA.
- |||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Trial completion date, Trial primary completion date: Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033) (clinicaltrials.gov) - Mar 5, 2024
P3, N=2000, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Switching to DOR/ISL 100/0.75mg maintains viral suppression for up to 96 weeks regardless of archived M184I/V or NNRTI RAMs in proviral DNA. Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2027
- ||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Trial completion date: Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) (clinicaltrials.gov) - Mar 3, 2024
P3, N=643, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2027 Trial completion date: May 2024 --> Feb 2025
- ||||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Enrollment closed: A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) (clinicaltrials.gov) - Jan 4, 2024
P3, N=650, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: May 2024 --> Feb 2025 Recruiting --> Active, not recruiting
- || doravirine/islatravir (MK-8591A) / Merck (MSD)
Trial completion: Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019) (clinicaltrials.gov) - Dec 8, 2023
P3, N=35, Completed, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Enrollment change: A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) (clinicaltrials.gov) - Nov 15, 2023
P3, N=650, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Active, not recruiting --> Completed N=1300 --> 650
- ||||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Enrollment closed: Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033) (clinicaltrials.gov) - Nov 7, 2023
P3, N=2000, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
N=1300 --> 650 Recruiting --> Active, not recruiting
- ||||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Enrollment closed: A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052) (clinicaltrials.gov) - Oct 12, 2023
P3, N=501, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- doravirine/islatravir (MK-8591A) / Merck (MSD)
Efficacy and safety by subgroup at week 48 after switch to doravirine/islatravir (100 mg/0.75 mg) once daily in two phase 3 trials (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_630;
P3
There were no clinically meaningful differences between treatment groups in the safety profile of P018 based on age, sex, race, or region. The higher rates of AEs in certain P017 DOR/ISL (100 mg/0.75 mg) subgroups can likely be attributed to the open-label study design.
- doravirine/islatravir (MK-8591A) / Merck (MSD)
Efficacy and safety by subgroup at week 48 after switch to doravirine/islatravir (100 mg/0.75 mg) once daily in two phase 3 trials (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_629;
P3
There were no clinically meaningful differences between treatment groups in the safety profile of P018 based on age, sex, race, or region. The higher rates of AEs in certain P017 DOR/ISL (100 mg/0.75 mg) subgroups can likely be attributed to the open-label study design.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, doravirine/islatravir (MK-8591A) / Merck (MSD)
Renal safety parameters of doravirine/islatravir (100/0.75 mg) vs bictegravir/emtricitabine/tenofovir alafenamide once-daily as initial HIV-1 treatment: week 48 results from a randomized, double-blind phase 3 trial (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_618;
P3
One participant in the B/F/TAF group experienced serious acute kidney injury and discontinued treatment. Conclusions :
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, doravirine/islatravir (MK-8591A) / Merck (MSD)
Renal safety parameters of doravirine/islatravir (100/0.75 mg) vs bictegravir/emtricitabine/tenofovir alafenamide once-daily as initial HIV-1 treatment: week 48 results from a randomized, double-blind phase 3 trial (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_617;
P3
One participant in the B/F/TAF group experienced serious acute kidney injury and discontinued treatment. Conclusions :
- doravirine/islatravir (MK-8591A) / Merck (MSD)
Subgroup analysis of week 48 efficacy and safety of doravirine/islatravir (100 mg/0.75 mg) once daily as initial HIV-1 treatment in a double-blind phase 3 trial (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_608;
P3
Conclusions : Purpose :
- doravirine/islatravir (MK-8591A) / Merck (MSD)
Subgroup analysis of week 48 efficacy and safety of doravirine/islatravir (100 mg/0.75 mg) once daily as initial HIV-1 treatment in a double-blind phase 3 trial (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_607;
P3
Purpose : Purpose :
- doravirine/islatravir (MK-8591A) / Merck (MSD)
Efficacy and safety of doravirine/islatravir (100 mg/0.75 mg) once daily in heavily treatment-experienced persons with HIV-1: week 49 results from a phase 3 trial (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_606;
P3
Purpose : Conclusions :
- doravirine/islatravir (MK-8591A) / Merck (MSD)
Efficacy and safety of doravirine/islatravir (100 mg/0.75 mg) once daily in heavily treatment-experienced persons with HIV-1: week 49 results from a phase 3 trial (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_605;
P3
Conclusions : Conclusions :
- ||||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Enrollment closed: A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051) (clinicaltrials.gov) - Sep 25, 2023
P3, N=501, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Conclusions : Recruiting --> Active, not recruiting
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, doravirine/islatravir (MK-8591A) / Merck (MSD)
Switch to fixed-dose doravirine/islatravir (100/0.75 mg) once daily in adults with HIV-1 virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamide: week 96 results of a phase 3, randomized, double-blind, non-inferiority trial (POLONEZ) - Sep 10, 2023 - Abstract #EACS2023EACS_223;
P3
Protocol-specified discontinuation criteria for CD4+ T-cell and/or TL count declines contributed to the efficacy difference between groups in the FAS. Decreases in cell counts accounted for many treatment-related AEs and discontinuations due to AEs with DOR/ISL.
- |||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Trial completion date, Trial primary completion date: DOR/ISL in HIV-1 Antiretroviral Treatment-na (clinicaltrials.gov) - Aug 18, 2023
P3, N=500, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Decreases in cell counts accounted for many treatment-related AEs and discontinuations due to AEs with DOR/ISL. Trial completion date: Jul 2026 --> Nov 2026 | Trial primary completion date: Mar 2025 --> Oct 2025
- | Pifeltro (doravirine) / Merck (MSD)
Preclinical, Journal: Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure. (Pubmed Central) - Jun 12, 2023
Doravirine showed favourable resistance profiles against viruses harbouring NRTI and NNRTI RAMs. The high barrier to resistance to doravirine coupled with the long intracellular half-life of islatravir may provide the opportunity for long-acting treatment options.
- doravirine/islatravir (MK-8591A) / Merck (MSD)
Weight and body composition after switch to doravirine/islatravir (DOR/ISL) 100/0.75mg once daily: week 48 results from 2 randomized active-controlled phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018) (Plaza Ballroom/Channel 3) - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_336;
The high barrier to resistance to doravirine coupled with the long intracellular half-life of islatravir may provide the opportunity for long-acting treatment options. Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- doravirine/islatravir (MK-8591A) / Merck (MSD)
Renal safety parameters after switch to doravirine/islatravir (DOR/ISL 100/0.75mg) once-daily: week 48 results from 2 randomized, active-controlled phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018) (Poster Exhibition area) - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_198;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- ||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Trial completion date: Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) (clinicaltrials.gov) - May 3, 2023
P3, N=643, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Trial completion date: Jan 2024 --> May 2024
- |||||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Enrollment open: A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) (clinicaltrials.gov) - Mar 23, 2023
P3, N=1300, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Jan 2024 --> May 2024 Not yet recruiting --> Recruiting
- |||||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Enrollment open: DOR/ISL in HIV-1 Antiretroviral Treatment-na (clinicaltrials.gov) - Mar 16, 2023
P3, N=500, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| doravirine/islatravir (MK-8591A) / Merck (MSD)
New P3 trial: A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) (clinicaltrials.gov) - Mar 13, 2023
P3, N=1300, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- |||||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Enrollment open: A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051) (clinicaltrials.gov) - Mar 6, 2023
P3, N=501, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Enrollment open: A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052) (clinicaltrials.gov) - Mar 2, 2023
P3, N=501, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || doravirine/islatravir (MK-8591A) / Merck (MSD)
Trial completion, Trial completion date: Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ?35 kg (MK-8591A-028) (clinicaltrials.gov) - Feb 24, 2023
P2, N=42, Completed, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Jan 2023
- |||||||||| doravirine/islatravir (MK-8591A) / Merck (MSD)
New P3 trial: DOR/ISL in HIV-1 Antiretroviral Treatment-na (clinicaltrials.gov) - Jan 30, 2023
P3, N=500, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- ||||| doravirine/islatravir (MK-8591A) / Merck (MSD)
Enrollment change, Trial completion date, Trial primary completion date: Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019) (clinicaltrials.gov) - Jan 6, 2023
P3, N=35, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Jan 2023 N=100 --> 35 | Trial completion date: Aug 2025 --> Oct 2023 | Trial primary completion date: Jul 2024 --> Nov 2022